Breaking News Instant updates and real-time market news.

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29

Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis

The Bristol-Myers Squibb-Pfizer Alliance announced results from retrospective real-world data analyses reporting outcomes on the safety and effectiveness of Eliquis compared to low molecular weight heparin or warfarin for the treatment of venous thromboembolism in patients with active cancer. The real-world data analyses were highlighted during oral presentations at the American Society of Hematology Annual Meeting. Results from the primary analysis showed that Eliquis use was associated with lower rates of major bleeding, clinically-relevant non-major bleeding and recurrent VTE compared to LMWH. Eliquis was also associated with a lower rate of recurrent VTE and similar rates of major bleeding and CRNM bleeding compared to warfarin, the Alliance said. Outcomes were defined based on diagnosis codes and setting of care. In a second oral presentation, results from a sub-group analysis of the primary study were highlighted based on different levels of risk for developing recurrent VTE, a blood clot most often found in the legs or lungs. Study findings were generally consistent with the primary analysis, it said.

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

PFE Pfizer
$38.29

0.26 (0.68%)

11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia Therapeutics upgraded to Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target. In a research note to investors, Seedhouse says Intellia's NTLA-2001 is poised to benefit from the "heavy lifting" Pfizer (PFE) is doing commercially with Vyndaqel in ATTR-cardiomyopathy, adding that Intellia is also advancing manufacturing related activities in support of a Phase 1 trial for engineered cell program WT1-TCR in AML. The analyst also says Intellia's lead gene editing program, NTLA-2001 has "really good" primate data showing TTR knockdown potentially better than Alnylam's (ALNY) patisiran. He expects the market will already start to impute downstream clinical benefit for NTLA-2001 after only a few patients with initial TTR knockdown data, because of the collective data for Ionis Pharmaceuticals' (IONS) inotersen and Alnylam's patisiran showing knockdown is relevant.
11/06/19
PIPR
11/06/19
NO CHANGE
Target $70
PIPR
Neutral
Ionis Pharmaceuticals price target lowered to $70 from $75 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target on Ionis Pharmaceuticals (IONS) to $70 and kept his Neutral rating after its Q3 results, saying that while the quarter was "strong" thanks to the recent $250M upfront payment from Pfizer (PFE), results for its Tegsedi were "uninspiring". The analyst states that an acceleration in Tegsedi is needed soon for him to become more positive on the name ahead of the "potential Phase I/II OLE +natural history Huntington's study readouts next year."
11/12/19
PIPR
11/12/19
NO CHANGE
Target $185
PIPR
Overweight
Time to dismiss Solid Biosciences as Sarepta competitor, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says that while she had dismissed Solid Biosciences' (SLDB) microdystophin gene therapy program as a competitive threat to Sarepta Therapeutics (SRPT), some investors worried that Solid could provide compelling data after adjusting protocol and moving up the dose. However, today's report of another clinical hold confirms that Solid's construct is toxic, indicating that Pfizer's (PFE) may to too, Brill tells investors in a research note. The analyst points out that both Solid and Pfizer use AAV9 and have had complement mediated serious adverse events after dosing just a few patients. Solid's program reaffirms her view that Sarepta's safety profile is differentiated. It is unlikely that the competition "is viable, let alone will ever catch up," says Brill. She keeps an Overweight rating on Sarepta Therapeutics with a $185 price target. The stock in midday trading is up 4% to $99.02 while Solid Biosciences is down 71% to $3.22.
11/25/19
PIPR
11/25/19
INITIATION
Target $2.5
PIPR
Overweight
Opko Health initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff initiated coverage of Opko Health (OPK) with an Overweight rating and $2.50 price target. The company's partner Pfizer (PFE) recently reported positive Phase III data on once-weekly somatrogo in pediatric growth hormone deficiency, Tenthoff tells investors in a research note. The analyst is confident in the drug and notes that Opko is eligible for up to $275M in milestones plus gross profit share on Genotropin and somatrogon revenue.
BMY Bristol-Myers
$59.94

0.435 (0.73%)

11/25/19
MZHO
11/25/19
INITIATION
Target $3.14
MZHO
Buy
Bristol-Myers Squibb CVR initiated with a Buy at Mizuho
Mizuho analyst Salim Syed initiated coverage of Bristol-Myers Squibb CVR with a Buy rating and $3.14 price target.
11/27/19
GABE
11/27/19
INITIATION
GABE
Buy
Bristol-Myers Squibb CVR initiated with a Buy at Gabelli
Gabelli analyst Kevin Kedra initiated coverage of Bristol-Myers Squibb CVR (BMY-R) with a Buy rating and private market value estimate of $3.50. CVR holders will receive a $9.00 payout if all three of the FDA approval milestones are met, Kedra tells investors in a research note. The analyst sees an 80% probability for the ozanimod milestone, an 86% probability for JCAR017, and 68% probability for bb2121. He recommends the Bristol-Myers CVR as an attractive risk/reward opportunity with multiple near-term catalysts.
11/27/19
11/27/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Vonage (VG) initiated with a Neutral at JPMorgan. 2. Bristol-Myers Squibb CVR (BMY-R, BMY) initiated with a Buy at Gabelli. 3. Novus Therapeutics (NVUS) initiated with a Buy at H.C. Wainwright. 4. KushCo Holdings (KSHB) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/03/19
MSCO
12/03/19
NO CHANGE
Target $100
MSCO
Equal Weight
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
Morgan Stanley analyst Matthew Harrison said he sees a high probability, or 75% odds, that Bluebird Bio (BLUE) shares will trade higher following the report of topline results from its KarMMa study of bb2121 as a fourth line or later therapy for the treatment of relapsed/refractory multiple myeloma, which are due by year-end. He said investors are focused on the median progression free survival delivered by the therapy as a gauge of its commercial viability versus other anti-BCMA CAR-T therapies in development at GlaxoSmithKline (GSK) and Bristol-Myers (BMY) in partnership with Regeneron (REGN). In a scenario where median PFS is greater than or equal to 11.5 months and overall response rate is greater than or equal to 85%, Harrison sees Bluebird shares having 20%-30% or more upside. If the median PFS is equal to or less than 9 months and ORR is below 80%, he thinks bb2121 would likely still be approvable, but sees shares down 10%-20%. In what he views as the most likely scenario - with mPFS of about 10 months and ORR of about 80% - Harrison sees 10%-20% upside in Bluebird shares. He keeps an Equal Weight rating and $100 price target on the stock.

TODAY'S FREE FLY STORIES

FB

Facebook

$220.95

-0.83 (-0.37%)

11:37
01/17/20
01/17
11:37
01/17/20
11:37
Periodicals
Facebook cuts Oculus Go price to $149 from $199, UploadVR reports »

Facebook said that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

WMT

Walmart

$115.15

-0.74 (-0.64%)

11:36
01/17/20
01/17
11:36
01/17/20
11:36
Hot Stocks
Walmart U.S. names Dacona Smith as incoming COO »

Walmart U.S. says Dacona…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

GOOGL

Alphabet Class A

$1,461.15

11.32 (0.78%)

, GOOG

Alphabet

$1,462.70

10.76 (0.74%)

11:33
01/17/20
01/17
11:33
01/17/20
11:33
Periodicals
Google working to bring Steam support to Chromebooks, Android Police says »

Kan Liu, director of…

GOOGL

Alphabet Class A

$1,461.15

11.32 (0.78%)

GOOG

Alphabet

$1,462.70

10.76 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

WMT

Walmart

$115.30

-0.59 (-0.51%)

11:28
01/17/20
01/17
11:28
01/17/20
11:28
Periodicals
Walmart chief merchant Steve Bratspies to depart, WSJ reports »

Walmart chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

NFLX

Netflix

$339.15

0.48 (0.14%)

11:25
01/17/20
01/17
11:25
01/17/20
11:25
Hot Stocks
Netflix opens new Paris office, boosts investment in France »

Netflix announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

11:25
01/17/20
01/17
11:25
01/17/20
11:25
General news
Philly Fed's Harker said the economy is looking "pretty good," »

Philly Fed's Harker…

AMED

Amedisys

$180.60

-0.59 (-0.33%)

11:25
01/17/20
01/17
11:25
01/17/20
11:25
Conference/Events
Amedisys participates in a conference call with Benchmark »

Healthcare Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

IBM

IBM

$137.15

-0.85 (-0.62%)

, PINS

Pinterest

$23.11

0.15 (0.65%)

11:24
01/17/20
01/17
11:24
01/17/20
11:24
On The Fly
IBM downgrade, Pinterest upgrade among today's top analyst calls »

Check out today's top…

IBM

IBM

$137.15

-0.85 (-0.62%)

PINS

Pinterest

$23.11

0.15 (0.65%)

EBAY

eBay

$35.69

-0.22 (-0.61%)

TWTR

Twitter

$34.11

-0.08 (-0.23%)

SNAP

Snap

$19.10

0.85 (4.66%)

QCOM

Qualcomm

$95.08

3.305 (3.60%)

WDC

Western Digital

$68.69

0.07 (0.10%)

LUV

Southwest

$55.31

0.01 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 28

    Jan

  • 30

    Jan

  • 04

    Feb

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

NCLH

Norwegian Cruise Line

$59.43

0.84 (1.43%)

11:21
01/17/20
01/17
11:21
01/17/20
11:21
Periodicals
Breaking Periodicals news story on Norwegian Cruise Line »

Hedgeye names Norwegian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
01/17/20
01/17
11:17
01/17/20
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
01/17/20
01/17
11:16
01/17/20
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$7.45

-0.49 (-6.17%)

11:15
01/17/20
01/17
11:15
01/17/20
11:15
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
01/17/20
01/17
11:10
01/17/20
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

STT

State Street

$84.45

3.445 (4.25%)

11:08
01/17/20
01/17
11:08
01/17/20
11:08
Periodicals
State Street held talks to find buyer for Currenex, FT reports »

State Street has held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
U.S. equities are modestly firmer at fresh record highs »

U.S. equities are…

ERIC

Ericsson

$9.01

-0.075 (-0.83%)

10:55
01/17/20
01/17
10:55
01/17/20
10:55
Options
Ericsson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

JBLU

JetBlue

$19.30

0.28 (1.47%)

10:45
01/17/20
01/17
10:45
01/17/20
10:45
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

10:40
01/17/20
01/17
10:40
01/17/20
10:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ES

Eversource

$87.74

0.01 (0.01%)

, CMS

CMS Energy

$65.28

-0.1 (-0.15%)

10:32
01/17/20
01/17
10:32
01/17/20
10:32
Downgrade
Eversource, CMS Energy, NextEra Energy rating change  »

NextEra, CMS Energy,…

ES

Eversource

$87.74

0.01 (0.01%)

CMS

CMS Energy

$65.28

-0.1 (-0.15%)

NEE

NextEra Energy

$251.86

-0.41 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

TWTR

Twitter

$34.14

-0.05 (-0.15%)

, SNAP

Snap

$19.15

0.9 (4.93%)

10:31
01/17/20
01/17
10:31
01/17/20
10:31
On The Fly
Analysts bullish on Pinterest, Snap as Twitter gets downgraded to Neutral »

Shares of social media…

TWTR

Twitter

$34.14

-0.05 (-0.15%)

SNAP

Snap

$19.15

0.9 (4.93%)

PINS

Pinterest

$23.30

0.34 (1.48%)

FB

Facebook

$221.31

-0.47 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Options
Busy week for 50 Cent as another massive block of calls is bought »

Busy week for 50 Cent as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

, KKR

KKR

$31.17

0.67 (2.20%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Periodicals
KKR not discussing going hostile on Dave & Buster's, Axios reports »

KKR (KKR) has a…

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

KKR

KKR

$31.17

0.67 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 31

    Jan

  • 26

    Feb

VWAGY

Volkswagen

$0.00

(0.00%)

10:28
01/17/20
01/17
10:28
01/17/20
10:28
Periodicals
VW set to acquire 20% stake in Chinese battery maker Guoxuan, Reuters reports »

Volkswagen is poised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIZI

Lizhi

$0.00

(0.00%)

10:26
01/17/20
01/17
10:26
01/17/20
10:26
Syndicate
Lizhi opens at $11.03, IPO priced at $11.00 per share »

Lizhi (LIZI) priced 4.1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.